Modality
siRNA
MOA
USP1i
Target
LAG-3
Pathway
Amyloid
CKD
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
Jul 2022
→ Apr 2031
Phase 2Current
NCT05174720
666 pts·CKD
2022-07→2031-04·Recruiting
666 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-245.1y awayPh2 Data· CKD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
Catalysts
Ph2 Data
2031-04-24 · 5.1y away
CKD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05174720 | Phase 2 | CKD | Recruiting | 666 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |